JP6078536B2 - Ｃ型肝炎ウイルス阻害剤 - Google Patents
Ｃ型肝炎ウイルス阻害剤 Download PDFInfo
- Publication number
- JP6078536B2 JP6078536B2 JP2014515914A JP2014515914A JP6078536B2 JP 6078536 B2 JP6078536 B2 JP 6078536B2 JP 2014515914 A JP2014515914 A JP 2014515914A JP 2014515914 A JP2014515914 A JP 2014515914A JP 6078536 B2 JP6078536 B2 JP 6078536B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- hcv
- halo
- mmol
- interferon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC(CCC[C@](C)[C@](*)C(N(C1)[C@]2C[C@]1Oc(nc1)c(cccc3)c3c1OC)=O)C=C[C@@](C1)[C@]1(C(N[S@@](C1CC1)=CC)=O)NC2=O Chemical compound CC(CCC[C@](C)[C@](*)C(N(C1)[C@]2C[C@]1Oc(nc1)c(cccc3)c3c1OC)=O)C=C[C@@](C1)[C@]1(C(N[S@@](C1CC1)=CC)=O)NC2=O 0.000 description 4
- WMBDDTUBUOEKTM-UHFFFAOYSA-N CC(C)(C)OC(N=C)=O Chemical compound CC(C)(C)OC(N=C)=O WMBDDTUBUOEKTM-UHFFFAOYSA-N 0.000 description 2
- BQVKJNVVQIBILF-UHFFFAOYSA-N COc(cn1)c(cccc2)c2c1[O]=C Chemical compound COc(cn1)c(cccc2)c2c1[O]=C BQVKJNVVQIBILF-UHFFFAOYSA-N 0.000 description 2
- OGYNFRCSDAUNAQ-FTVKEXHGSA-N C[C@H](CCC[C@@H](C)/C=C\[C@H](C1)[C@]1(C(NS(C1CC1)(=O)=O)=O)NC([C@H](C[C@H](C1)Oc(nc2)c(ccc(OC)c3)c3c2OC)N1C1=O)=O)[C@@H]1NC(OC(C)(C)C(F)(F)F)=O Chemical compound C[C@H](CCC[C@@H](C)/C=C\[C@H](C1)[C@]1(C(NS(C1CC1)(=O)=O)=O)NC([C@H](C[C@H](C1)Oc(nc2)c(ccc(OC)c3)c3c2OC)N1C1=O)=O)[C@@H]1NC(OC(C)(C)C(F)(F)F)=O OGYNFRCSDAUNAQ-FTVKEXHGSA-N 0.000 description 2
- VCTQGDNFILRGER-UHFFFAOYSA-N CC(C)(C(F)(F)F)OC(N=C)=O Chemical compound CC(C)(C(F)(F)F)OC(N=C)=O VCTQGDNFILRGER-UHFFFAOYSA-N 0.000 description 1
- QXVZMMCQAYIZOI-SHARSMKWSA-N CCOC(C([C@H](C)CCCC(C)C=C)NC(OC(C)(C)C)=O)=O Chemical compound CCOC(C([C@H](C)CCCC(C)C=C)NC(OC(C)(C)C)=O)=O QXVZMMCQAYIZOI-SHARSMKWSA-N 0.000 description 1
- ITVVDKFBWYVGPV-UHFFFAOYSA-N COc(c1c2cccc1)cnc2O Chemical compound COc(c1c2cccc1)cnc2O ITVVDKFBWYVGPV-UHFFFAOYSA-N 0.000 description 1
- BRRYKXRVCAAAHT-UBVCNFCFSA-N C[C@H](CCCC(C)C=C)[C@@H](C(N(C[C@@H](C1)Oc(nc2)c(cccc3)c3c2OC)[C@@H]1C(N[C@](C1)([C@@H]1C=C)C(N/S(/C1CC1)=C/C)=O)=O)=O)NC(OC(C)(C)C)=O Chemical compound C[C@H](CCCC(C)C=C)[C@@H](C(N(C[C@@H](C1)Oc(nc2)c(cccc3)c3c2OC)[C@@H]1C(N[C@](C1)([C@@H]1C=C)C(N/S(/C1CC1)=C/C)=O)=O)=O)NC(OC(C)(C)C)=O BRRYKXRVCAAAHT-UBVCNFCFSA-N 0.000 description 1
- GYUKXXHNALVLON-WXISSYIKSA-N C[C@H](CCC[C@@H](C)/C=C\[C@H](C1)[C@@]1(C)C(NS(C1(C)CC1)(=O)=O)=O)[C@@H](C(N(C[C@@H](C1)Oc(nc2)c(cccc3Cl)c3c2OC)[C@@H]1C(N)=O)=O)NC(OC(C)(C)C(F)(F)F)=O Chemical compound C[C@H](CCC[C@@H](C)/C=C\[C@H](C1)[C@@]1(C)C(NS(C1(C)CC1)(=O)=O)=O)[C@@H](C(N(C[C@@H](C1)Oc(nc2)c(cccc3Cl)c3c2OC)[C@@H]1C(N)=O)=O)NC(OC(C)(C)C(F)(F)F)=O GYUKXXHNALVLON-WXISSYIKSA-N 0.000 description 1
- XPVROWXOSCLZJL-MAQNSRBKSA-N C[C@H](CCC[C@@H](C)/C=C\[C@H](C1)[C@]1(C(N/S(/C1CC1)=C/C)=O)NC([C@H](C[C@H](C1)Oc2nc(ccc(OC)c3)c3nc2)N1C1=O)=O)[C@@H]1NC(OC(C)(C)C)=O Chemical compound C[C@H](CCC[C@@H](C)/C=C\[C@H](C1)[C@]1(C(N/S(/C1CC1)=C/C)=O)NC([C@H](C[C@H](C1)Oc2nc(ccc(OC)c3)c3nc2)N1C1=O)=O)[C@@H]1NC(OC(C)(C)C)=O XPVROWXOSCLZJL-MAQNSRBKSA-N 0.000 description 1
- NUNVFFBWYZOEQJ-LVUCJLHGSA-N C[C@H](CCC[C@@H](C)/C=C\[C@H](C1)[C@]1(C(N/S(/C1CC1)=C/C)=O)NC([C@H]1N2CCC1)=O)CC2=O Chemical compound C[C@H](CCC[C@@H](C)/C=C\[C@H](C1)[C@]1(C(N/S(/C1CC1)=C/C)=O)NC([C@H]1N2CCC1)=O)CC2=O NUNVFFBWYZOEQJ-LVUCJLHGSA-N 0.000 description 1
- GMKCUAUZUBXIMA-JMKAVEGQSA-N C[C@H](CCC[C@@H](C)/C=C\[C@H](C1)[C@]1(C(NS(C1CC1)(=O)=O)=O)NC([C@H](C[C@H](C1)Oc(nc2)c(cc(cc3)F)c3c2OC)N1C1=O)=O)[C@@H]1NC(OC(C)(C)C(F)(F)F)=O Chemical compound C[C@H](CCC[C@@H](C)/C=C\[C@H](C1)[C@]1(C(NS(C1CC1)(=O)=O)=O)NC([C@H](C[C@H](C1)Oc(nc2)c(cc(cc3)F)c3c2OC)N1C1=O)=O)[C@@H]1NC(OC(C)(C)C(F)(F)F)=O GMKCUAUZUBXIMA-JMKAVEGQSA-N 0.000 description 1
- SFYVIJSLWJFQMF-VMROBCOOSA-N C[C@H](CCC[C@@H](C)/C=C\[C@H](C1)[C@]1(C(NS(C1CC1)(=O)=O)=O)NC([C@H](C[C@H](C1)Oc(nc2)c(ccc(OC)c3)c3c2OC)N1C1=O)=O)[C@@H]1NC(OC(C)(C)C)=O Chemical compound C[C@H](CCC[C@@H](C)/C=C\[C@H](C1)[C@]1(C(NS(C1CC1)(=O)=O)=O)NC([C@H](C[C@H](C1)Oc(nc2)c(ccc(OC)c3)c3c2OC)N1C1=O)=O)[C@@H]1NC(OC(C)(C)C)=O SFYVIJSLWJFQMF-VMROBCOOSA-N 0.000 description 1
- YUAYEOCECLXPKP-DYDAHKGKSA-N C[C@H](CCC[C@@H](C)/C=C\[C@H](C1)[C@]1(C(NS(C1CC1)=O)=O)NC([C@H](C[C@H](C1)Oc(nc2)c(ccc(OC)c3)c3c2OC)N1C1=O)=O)[C@@H]1NC(OC(C)(C)C)=O Chemical compound C[C@H](CCC[C@@H](C)/C=C\[C@H](C1)[C@]1(C(NS(C1CC1)=O)=O)NC([C@H](C[C@H](C1)Oc(nc2)c(ccc(OC)c3)c3c2OC)N1C1=O)=O)[C@@H]1NC(OC(C)(C)C)=O YUAYEOCECLXPKP-DYDAHKGKSA-N 0.000 description 1
- RIYODWLHOJRUCU-SAPHJPISSA-N C[C@H](CCC[C@@H](C)/C=C\[C@H](C1)[C@]1(C(NSC1CC1)=O)NC([C@H]1N2CCC1)=O)CC2=O Chemical compound C[C@H](CCC[C@@H](C)/C=C\[C@H](C1)[C@]1(C(NSC1CC1)=O)NC([C@H]1N2CCC1)=O)CC2=O RIYODWLHOJRUCU-SAPHJPISSA-N 0.000 description 1
- JHYYUHMCQYCWAV-XRWWVIAHSA-N C[C@H](CCC[C@@H](C)/C=C\[C@H](C1)[C@]1(C(N[SiH2]C1CC1)=O)NC([C@H](C[C@H](C1)Oc2nc(cc(cc3)OC)c3nc2)N1C1=O)=O)[C@@H]1NC(OC(C)(C)C(F)(F)F)=O Chemical compound C[C@H](CCC[C@@H](C)/C=C\[C@H](C1)[C@]1(C(N[SiH2]C1CC1)=O)NC([C@H](C[C@H](C1)Oc2nc(cc(cc3)OC)c3nc2)N1C1=O)=O)[C@@H]1NC(OC(C)(C)C(F)(F)F)=O JHYYUHMCQYCWAV-XRWWVIAHSA-N 0.000 description 1
- OCNZKERDADTXCZ-DLYUBGHWSA-N C[C@H](CCC[C@@H](C)/C=C\[C@H](C1)[C@]1(CC(NS(C1(C)CC1)(=O)=O)=O)NC([C@H](C[C@H](C1)Oc(nc2)c(ccc(OC)c3)c3c2OC)N1C1=O)=O)[C@@H]1NC(OC(C)(C)C(F)(F)F)=O Chemical compound C[C@H](CCC[C@@H](C)/C=C\[C@H](C1)[C@]1(CC(NS(C1(C)CC1)(=O)=O)=O)NC([C@H](C[C@H](C1)Oc(nc2)c(ccc(OC)c3)c3c2OC)N1C1=O)=O)[C@@H]1NC(OC(C)(C)C(F)(F)F)=O OCNZKERDADTXCZ-DLYUBGHWSA-N 0.000 description 1
- VUEPOCNGLHFECA-JBAHQMPISA-N C[C@H](CCC[C@H](C)/C=C\[C@H](C1)[C@]1(C(NS(C1CC1)=O)=O)NC([C@H](C[C@H](C1)Oc2nc(ccc(OC)c3)c3nc2)N1C1=O)=O)[C@@H]1NC(OC(C)(C)C)=O Chemical compound C[C@H](CCC[C@H](C)/C=C\[C@H](C1)[C@]1(C(NS(C1CC1)=O)=O)NC([C@H](C[C@H](C1)Oc2nc(ccc(OC)c3)c3nc2)N1C1=O)=O)[C@@H]1NC(OC(C)(C)C)=O VUEPOCNGLHFECA-JBAHQMPISA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161497141P | 2011-06-15 | 2011-06-15 | |
| US61/497,141 | 2011-06-15 | ||
| PCT/US2012/042038 WO2012173983A1 (en) | 2011-06-15 | 2012-06-12 | Hepatitis c virus inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014522809A JP2014522809A (ja) | 2014-09-08 |
| JP2014522809A5 JP2014522809A5 (enExample) | 2015-07-09 |
| JP6078536B2 true JP6078536B2 (ja) | 2017-02-08 |
Family
ID=46331708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014515914A Expired - Fee Related JP6078536B2 (ja) | 2011-06-15 | 2012-06-12 | Ｃ型肝炎ウイルス阻害剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8691757B2 (enExample) |
| EP (1) | EP2721053B1 (enExample) |
| JP (1) | JP6078536B2 (enExample) |
| AR (1) | AR086934A1 (enExample) |
| BR (1) | BR112013032049A2 (enExample) |
| CA (1) | CA2839400A1 (enExample) |
| EA (1) | EA024173B1 (enExample) |
| ES (1) | ES2604690T3 (enExample) |
| MX (1) | MX2013014002A (enExample) |
| TW (1) | TW201305173A (enExample) |
| WO (1) | WO2012173983A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7893264B2 (en) | 2006-07-07 | 2011-02-22 | Gilead Sciences, Inc. | Antiviral phosphinate compounds |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
| JP6154474B2 (ja) | 2012-10-19 | 2017-06-28 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃ型肝炎ウイルス阻害剤 |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2014071007A1 (en) * | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| EP2914613B1 (en) | 2012-11-02 | 2017-11-22 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| EP2914614B1 (en) | 2012-11-05 | 2017-08-16 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| CN103113324B (zh) * | 2013-02-07 | 2015-08-05 | 浙江工业大学 | 一种n-磺酰基取代的四氢吡咯类化合物的制备方法 |
| EP2964664B1 (en) * | 2013-03-07 | 2017-01-11 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| JP6511432B2 (ja) | 2013-03-15 | 2019-05-15 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃ型肝炎ウイルスの大環状二環式阻害剤 |
Family Cites Families (177)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0475255A3 (en) | 1990-09-12 | 1993-04-14 | F. Hoffmann-La Roche Ag | Process for the preparation of optically pure (s)-alpha-((tert-butylsulfonyl)methyl)hydro cinnamic acid |
| NZ335276A (en) | 1996-10-18 | 2000-09-29 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis C virus (HCV) NS3 (Non Structural Protein 3) protease |
| IL134232A0 (en) | 1997-08-11 | 2001-04-30 | Boehringer Ingelheim Ca Ltd | Hepatitis c inhibitor peptides |
| PT1012180E (pt) | 1997-08-11 | 2005-04-29 | Boehringer Ingelheim Ca Ltd | Analogos de peptidos inibidores da hepatite c |
| AR022061A1 (es) | 1998-08-10 | 2002-09-04 | Boehringer Ingelheim Ca Ltd | Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos. |
| US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
| US6608027B1 (en) * | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
| US7012066B2 (en) | 2000-07-21 | 2006-03-14 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
| US7244721B2 (en) | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
| MXPA03004299A (es) | 2000-11-20 | 2004-02-12 | Bristol Myers Squibb Co | Inhibidores de tripeptido de hepatitis c. |
| US6867185B2 (en) | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| CA2369711A1 (en) | 2002-01-30 | 2003-07-30 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis c virus |
| CA2370396A1 (en) | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
| CA2369970A1 (en) | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
| US6828301B2 (en) | 2002-02-07 | 2004-12-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
| PL215228B1 (pl) | 2002-05-20 | 2013-11-29 | Bristol Myers Squibb Co | Zwiazki tripeptydowe, ich zastosowanie i kompozycja farmaceutyczna je zawierajaca oraz jej zastosowanie |
| US20060199773A1 (en) | 2002-05-20 | 2006-09-07 | Sausker Justin B | Crystalline forms of (1R,2S)-N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide, monopotassium salt |
| ES2315568T3 (es) | 2002-05-20 | 2009-04-01 | Bristol-Myers Squibb Company | Inhibidores del virus de la hepatitis c basados en cicloalquilo p1' sustituido. |
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| AU2003248535A1 (en) | 2002-05-20 | 2003-12-12 | Bristol-Myers Squibb Company | Heterocyclicsulfonamide hepatitis c virus inhibitors |
| US20040033959A1 (en) | 2002-07-19 | 2004-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
| US20050075279A1 (en) | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
| US7601709B2 (en) | 2003-02-07 | 2009-10-13 | Enanta Pharmaceuticals, Inc. | Macrocyclic hepatitis C serine protease inhibitors |
| CN1771050A (zh) | 2003-02-07 | 2006-05-10 | 益安药业 | 丙型肝炎丝氨酸蛋白酶的大环抑制剂 |
| JP4550824B2 (ja) | 2003-03-05 | 2010-09-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃ型肝炎抑制化合物 |
| DE602004029866D1 (de) | 2003-03-05 | 2010-12-16 | Boehringer Ingelheim Pharma | Peptidanaloga mit inhibitorischer wirkung auf hepatitis c |
| RS20050741A (sr) | 2003-04-02 | 2007-06-04 | Boehringer Ingelheim International Gmbh., | Farmaceutske kompozicije za inhibitore virusne proteaze hepatitisa c |
| ATE422895T1 (de) * | 2003-04-16 | 2009-03-15 | Bristol Myers Squibb Co | Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus |
| WO2004093798A2 (en) | 2003-04-18 | 2004-11-04 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis c serine protease inhibitors |
| CL2004001161A1 (es) | 2003-05-21 | 2005-04-08 | Boehringer Ingelheim Int | Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c. |
| WO2004113365A2 (en) | 2003-06-05 | 2004-12-29 | Enanta Pharmaceuticals, Inc. | Hepatitis c serine protease tri-peptide inhibitors |
| US7125845B2 (en) | 2003-07-03 | 2006-10-24 | Enanta Pharmaceuticals, Inc. | Aza-peptide macrocyclic hepatitis C serine protease inhibitors |
| EP1673385B1 (en) | 2003-09-22 | 2011-03-02 | Boehringer Ingelheim International GmbH | Macrocyclic peptides active against the hepatitis c virus |
| NZ546663A (en) | 2003-10-10 | 2010-01-29 | Vertex Pharma | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| WO2005037214A2 (en) | 2003-10-14 | 2005-04-28 | Intermune, Inc. | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication |
| US7132504B2 (en) | 2003-11-12 | 2006-11-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7135462B2 (en) | 2003-11-20 | 2006-11-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7309708B2 (en) | 2003-11-20 | 2007-12-18 | Birstol-Myers Squibb Company | Hepatitis C virus inhibitors |
| MXPA06005683A (es) | 2003-11-20 | 2006-12-14 | Schering Corp | Inhibidores despeptidizados de la proteasa ns3 del virus de la hepatitis c. |
| WO2005070955A1 (en) | 2004-01-21 | 2005-08-04 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis c virus |
| ES2336009T3 (es) | 2004-01-30 | 2010-04-07 | Medivir Ab | Inhibidores de la ns-3 serina proteasa del vhc. |
| ES2338666T3 (es) | 2004-03-15 | 2010-05-11 | Boehringer Ingelheim International Gmbh | Procedimiento para la preparacion de dipeptidos macrociclicos adecuados para el tratamiento de infecciones viricas de la hepatitis c. |
| EP1749007A2 (en) | 2004-03-30 | 2007-02-07 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
| WO2006016930A2 (en) | 2004-05-14 | 2006-02-16 | Intermune, Inc. | Methods for treating hcv infection |
| EP1753775B1 (en) | 2004-05-25 | 2012-12-26 | Boehringer Ingelheim International GmbH | Process for preparing acyclic hcv protease inhibitors |
| JP4914348B2 (ja) | 2004-06-28 | 2012-04-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃ型肝炎インヒビターペプチド類似体 |
| KR20070034119A (ko) | 2004-07-16 | 2007-03-27 | 길리애드 사이언시즈, 인코포레이티드 | 항바이러스 화합물 |
| UY29016A1 (es) | 2004-07-20 | 2006-02-24 | Boehringer Ingelheim Int | Analogos de dipeptidos inhibidores de la hepatitis c |
| JP4914355B2 (ja) | 2004-07-20 | 2012-04-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃ型肝炎インヒビターペプチド類似体 |
| MX2007002371A (es) | 2004-08-27 | 2007-04-23 | Schering Corp | Compuestos de acilsulfonamida como inhibidores de la serina proteasa ns3 del virus de la hepatitis c. |
| US7375218B2 (en) | 2004-09-17 | 2008-05-20 | Boehringer Ingelheim International Gmbh | Process for preparing macrocyclic HCV protease inhibitors |
| WO2007001406A2 (en) | 2004-10-05 | 2007-01-04 | Chiron Corporation | Aryl-containing macrocyclic compounds |
| MX2007004783A (es) | 2004-10-21 | 2007-05-11 | Pfizer | Inhibidores de la proteasa del virus de la hepatitis c, y composiciones y tratamientos que los usan. |
| US7323447B2 (en) | 2005-02-08 | 2008-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN103172697A (zh) | 2005-03-08 | 2013-06-26 | 贝林格尔.英格海姆国际有限公司 | 制备大环化合物的方法 |
| AU2006242475B2 (en) | 2005-05-02 | 2011-07-07 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
| US7592336B2 (en) | 2005-05-10 | 2009-09-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7772178B2 (en) | 2005-06-02 | 2010-08-10 | Schering Corporation | Pharmaceutical formulations and methods of treatment using the same |
| US20060287248A1 (en) | 2005-06-02 | 2006-12-21 | Schering Corporation | Asymmetric dosing methods |
| JP2008545748A (ja) | 2005-06-02 | 2008-12-18 | シェーリング コーポレイション | Ｃ型肝炎ウイルスに関連する障害を処置するために有用な徐放処方物 |
| WO2006130552A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis c virus |
| WO2006130666A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Medicaments and methods combining a hcv protease inhibitor and an akr competitor |
| US20070004635A1 (en) | 2005-06-02 | 2007-01-04 | Schering Corporation | Method of treating interferon non-responders using HCV protease inhibitor |
| US20060281689A1 (en) | 2005-06-02 | 2006-12-14 | Schering Corporation | Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period |
| US8119602B2 (en) | 2005-06-02 | 2012-02-21 | Schering Corporation | Administration of HCV protease inhibitors in combination with food to improve bioavailability |
| US20060276407A1 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis C virus |
| US20060276405A1 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods for treating hepatitis C |
| US20070021351A1 (en) | 2005-06-02 | 2007-01-25 | Schering Corporation | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor |
| US7601686B2 (en) | 2005-07-11 | 2009-10-13 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TWI389908B (zh) | 2005-07-14 | 2013-03-21 | Gilead Sciences Inc | 抗病毒化合物類 |
| TW200738742A (en) | 2005-07-14 | 2007-10-16 | Gilead Sciences Inc | Antiviral compounds |
| US20080200497A1 (en) | 2005-07-20 | 2008-08-21 | Bailey Murray D | Hepatitis C Inhibitor Peptide Analogs |
| AR057456A1 (es) | 2005-07-20 | 2007-12-05 | Merck & Co Inc | Inhibidores de la proteasa ns3 del vhc |
| EP2305696A3 (en) | 2005-07-25 | 2011-10-12 | Intermune, Inc. | Macrocyclic inhibitors of Hepatitis C virus replication |
| PE20070343A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Inhibidores macrociclicos del virus de la hepatitis c |
| PE20070210A1 (es) | 2005-07-29 | 2007-04-16 | Tibotec Pharm Ltd | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
| BRPI0614637A2 (pt) | 2005-07-29 | 2011-04-12 | Tibotec Pharm Ltd | inibidores macrocìclicos do vìrus da hepatite c |
| AR055105A1 (es) | 2005-07-29 | 2007-08-08 | Tibotec Pharm Ltd | Inhibidores macrociclicos del virus de la hepatitis c |
| EP1919904B1 (en) | 2005-07-29 | 2014-01-08 | Janssen R&D Ireland | Macrocyclic inhibitors of hepatitis c virus |
| PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
| JO2768B1 (en) | 2005-07-29 | 2014-03-15 | تيبوتيك فارماسيوتيكالز ليمتد | Large cyclic inhibitors of hepatitis C virus |
| WO2007014922A1 (en) | 2005-07-29 | 2007-02-08 | Tibotec Pharmaceuticals Ltd. | Macrocyclic inhibitors of hepatitis c virus |
| RU2436787C2 (ru) | 2005-07-29 | 2011-12-20 | Тиботек Фармасьютикалз Лтд. | Макроциклические ингибиторы вируса гепатита с |
| ATE496042T1 (de) | 2005-07-29 | 2011-02-15 | Tibotec Pharm Ltd | Makrocyclische inhibitoren des hepatitis-c-virus |
| EP1910347A2 (en) | 2005-07-29 | 2008-04-16 | Medivir Ab | Macrocylic inhibitors of hepatitis c virus |
| US8278322B2 (en) | 2005-08-01 | 2012-10-02 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
| WO2007016476A2 (en) | 2005-08-01 | 2007-02-08 | Phenomix Corporation | Hepatitis c serine protease inhibitors and uses therefor |
| AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
| EA200801050A1 (ru) | 2005-10-11 | 2008-12-30 | Интермьюн, Инк. | Соединения и способы ингибирования репликации вирусного гепатита с |
| US7772183B2 (en) | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2007082131A1 (en) | 2006-01-09 | 2007-07-19 | Bristol-Myers Squibb Company | Process for the preparation of hydroxy substituted heterocycles |
| JP2009528353A (ja) | 2006-03-03 | 2009-08-06 | シェーリング コーポレイション | Ｈｃｖのプロテアーゼ阻害剤およびｉｒｅｓ阻害剤の医薬的組み合わせ |
| GB0609492D0 (en) | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| US8268776B2 (en) | 2006-06-06 | 2012-09-18 | Enanta Pharmaceuticals, Inc. | Macrocylic oximyl hepatitis C protease inhibitors |
| US20070281884A1 (en) | 2006-06-06 | 2007-12-06 | Ying Sun | Macrocyclic oximyl hepatitis C protease inhibitors |
| GB0612423D0 (en) | 2006-06-23 | 2006-08-02 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| UY30437A1 (es) | 2006-06-26 | 2008-01-31 | Enanta Pharm Inc | Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c |
| RU2008152171A (ru) | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | Новые ингибиторы вирусной репликации гепатита с |
| US7893264B2 (en) | 2006-07-07 | 2011-02-22 | Gilead Sciences, Inc. | Antiviral phosphinate compounds |
| WO2008008776A2 (en) | 2006-07-11 | 2008-01-17 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| ES2448494T3 (es) | 2006-07-13 | 2014-03-14 | Achillion Pharmaceuticals, Inc. | Péptidos de 4-amino-4-oxobutanoilo en calidad de inhibidores de la replicación viral |
| WO2008019303A2 (en) | 2006-08-04 | 2008-02-14 | Enanta Pharmaceuticals, Inc. | Pyridazinonyl macrocyclic hepatitis c serine protease inhibitors |
| CN101674844A (zh) | 2006-08-04 | 2010-03-17 | 英安塔制药有限公司 | 四唑基大环类c型肝炎丝氨酸蛋白酶抑制剂 |
| US20090035267A1 (en) | 2007-07-31 | 2009-02-05 | Moore Joel D | Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors |
| US7635683B2 (en) | 2006-08-04 | 2009-12-22 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl tripeptide hepatitis C virus inhibitors |
| US20080038225A1 (en) | 2006-08-11 | 2008-02-14 | Ying Sun | Triazolyl acyclic hepatitis c serine protease inhibitors |
| US7582605B2 (en) | 2006-08-11 | 2009-09-01 | Enanta Pharmaceuticals, Inc. | Phosphorus-containing hepatitis C serine protease inhibitors |
| WO2008021960A2 (en) | 2006-08-11 | 2008-02-21 | Enanta Pharmaceuticals, Inc. | Triazolyl macrocyclic hepatitis c serine protease inhibitors |
| WO2008022006A2 (en) | 2006-08-11 | 2008-02-21 | Enanta Pharmaceuticals, Inc. | Arylalkoxyl hepatitis c virus protease inhibitors |
| US20090035268A1 (en) | 2007-08-01 | 2009-02-05 | Ying Sun | Tetrazolyl acyclic hepatitis c serine protease inhibitors |
| US7605126B2 (en) | 2006-08-11 | 2009-10-20 | Enanta Pharmaceuticals, Inc. | Acylaminoheteroaryl hepatitis C virus protease inhibitors |
| CA2667165A1 (en) | 2006-10-24 | 2008-05-02 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
| CN101583372A (zh) | 2006-10-24 | 2009-11-18 | 默克公司 | Hcv ns3蛋白酶抑制剂 |
| US8138164B2 (en) | 2006-10-24 | 2012-03-20 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
| JP5268927B2 (ja) | 2006-10-27 | 2013-08-21 | メルク・シャープ・アンド・ドーム・コーポレーション | Ｈｃｖｎｓ３プロテアーゼ阻害剤 |
| WO2008057208A2 (en) | 2006-10-27 | 2008-05-15 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
| US20080107625A1 (en) | 2006-11-01 | 2008-05-08 | Bristol-Myers Squibb Company | Inhibitors of Hepatitis C Virus |
| US20080107623A1 (en) | 2006-11-01 | 2008-05-08 | Bristol-Myers Squibb Company | Inhibitors of Hepatitis C Virus |
| US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| WO2008057995A2 (en) | 2006-11-02 | 2008-05-15 | Taigen Biotechnology Co., Ltd. | Hcv protease inhibitors |
| US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2008070358A2 (en) | 2006-11-16 | 2008-06-12 | Phenomix Corporation | N-cyclopropyl-hydroxyproline-based tripeptidic hepatitis c serine protease inhibitors containing an isoindole, pyrrolopyridine, pyrrolopyrimidine or pyrrolopyrazine heterocycle in the side chain |
| US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2008059046A1 (en) | 2006-11-17 | 2008-05-22 | Tibotec Pharmaceuticals Ltd. | Macrocyclic inhibitors of hepatitis c virus |
| SI2118098T1 (sl) | 2007-02-01 | 2015-01-30 | Janssen R&D Ireland | Polimorfne oblike makrocikličnega inhibitorja HCV |
| RU2483067C2 (ru) | 2007-02-01 | 2013-05-27 | Тиботек Фармасьютикалз Лтд. | Способы и промежуточные продукты для получения макроциклического ингибитора протеазы вируса гепатита с |
| US20080207528A1 (en) | 2007-02-01 | 2008-08-28 | Syaulan Yang | Hcv protease inhibitors |
| RU2481340C2 (ru) | 2007-02-08 | 2013-05-10 | Тиботек Фармасьютикалз Лтд. | Пиримидин-замещенные макроциклические ингибиторы hcv |
| WO2008096002A1 (en) | 2007-02-08 | 2008-08-14 | Tibotec Pharmaceuticals Ltd. | Hcv inhibiting macrocyclic phosphonates and amidophosphates |
| MX2009008541A (es) | 2007-02-08 | 2009-08-18 | Tibotec Pharm Ltd | Fenilcarbamatos macrociclicos que inhiben el virus de hepatitis c. |
| JP2010518128A (ja) | 2007-02-16 | 2010-05-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃ型肝炎ｎｓ３プロテアーゼのインヒビター |
| BRPI0807887A2 (pt) | 2007-02-20 | 2014-06-17 | Novartis Ag | Compostos macrocíclicos como inibidores de hcv ns3 protease. |
| EP2125113A2 (en) | 2007-02-26 | 2009-12-02 | Achillion Pharmaceuticals, Inc. | Tertiary amine substituted peptides useful as inhibitors of hcv replication |
| ES2355437T3 (es) | 2007-04-24 | 2011-03-25 | F. Hoffmann-La Roche Ag | Procedimiento para un intermediario de inhibidores de proteasa del vhc. |
| WO2008134395A1 (en) | 2007-04-26 | 2008-11-06 | Enanta Pharmaceuticals, Inc. | Aza-peptide macrocyclic hepatitis c serine protease inhibitors |
| US20080279821A1 (en) | 2007-04-26 | 2008-11-13 | Deqiang Niu | Arylpiperidinyl and arylpyrrolidinyl macrocyclic hepatitis c serine protease inhibitors |
| WO2008134397A1 (en) | 2007-04-26 | 2008-11-06 | Enanta Pharmaceuticals, Inc. | Aza-tripeptide hepatitis c serine protease inhibitors |
| US20080292587A1 (en) | 2007-04-26 | 2008-11-27 | Ying Sun | Oximyl dipeptide hepatitis c protease inhibitors |
| WO2008137779A2 (en) | 2007-05-03 | 2008-11-13 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
| CA2686546A1 (en) | 2007-05-10 | 2008-11-20 | Intermune, Inc. | Novel peptide inhibitors of hepatitis c virus replication |
| AR068794A1 (es) | 2007-06-29 | 2009-12-09 | Gilead Sciences Inc | Compuestos antivirales |
| AR067180A1 (es) | 2007-06-29 | 2009-09-30 | Gilead Sciences Inc | Compuestos antivirales |
| CN101754974B (zh) | 2007-07-19 | 2016-02-03 | Msd意大利有限公司 | 作为抗病毒剂的大环化合物 |
| WO2009014730A1 (en) | 2007-07-26 | 2009-01-29 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
| US8263549B2 (en) | 2007-11-29 | 2012-09-11 | Enanta Pharmaceuticals, Inc. | C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors |
| US8309685B2 (en) | 2007-12-21 | 2012-11-13 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
| US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
| CN104557880A (zh) | 2007-12-21 | 2015-04-29 | 阿维拉制药公司 | Hcv蛋白酶抑制剂和其用途 |
| WO2009142842A2 (en) | 2008-04-15 | 2009-11-26 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
| US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US20090285774A1 (en) | 2008-05-15 | 2009-11-19 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20090285773A1 (en) | 2008-05-15 | 2009-11-19 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN102046648A (zh) | 2008-05-29 | 2011-05-04 | 百时美施贵宝公司 | 丙型肝炎病毒抑制剂 |
| WO2010031832A2 (en) | 2008-09-18 | 2010-03-25 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc | Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative |
| TW201023858A (en) | 2008-09-18 | 2010-07-01 | Ortho Mcneil Janssen Pharm | Synergistic combinations of a macrocyclic inhibitor of HCV and a nucleoside |
| US20100080770A1 (en) | 2008-09-29 | 2010-04-01 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US20100272674A1 (en) | 2008-12-04 | 2010-10-28 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8232246B2 (en) | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
| PE20120322A1 (es) | 2009-07-07 | 2012-04-14 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende faldaprevir o una sal del mismo en un vehiculo auto-emulsionante |
| CN105001302A (zh) | 2009-09-28 | 2015-10-28 | 英特穆恩公司 | C型肝炎病毒复制的环肽抑制剂 |
| MX2012003171A (es) | 2009-09-28 | 2012-04-11 | Hoffmann La Roche | Novedosos inhibidores macrociclicos de la replicacion del virus de hepatitis c. |
| US8415374B2 (en) | 2009-10-12 | 2013-04-09 | Bristol-Myers Squibb Company | Combinations of hepatitis C virus inhibitors |
| WO2011063502A1 (en) | 2009-11-24 | 2011-06-03 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor compounds |
| MX2012007076A (es) | 2009-12-18 | 2012-07-20 | Boehringer Ingelheim Int | Terapia combinada de hcv. |
| US20120196794A1 (en) | 2010-08-06 | 2012-08-02 | Bristol-Myers Squibb Company | Combinations of Hepatitis C Virus Inhibitors |
| US20120095211A1 (en) | 2010-09-22 | 2012-04-19 | Intermune, Inc. | Substituted proline inhibitors of hepatitis c virus replication |
| KR20140003521A (ko) | 2010-12-30 | 2014-01-09 | 이난타 파마슈티칼스, 인코포레이티드 | 페난트리딘 매크로사이클릭 ｃ형 간염 세린 프로테아제 억제제 |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2012166459A1 (en) | 2011-05-27 | 2012-12-06 | Bristol-Myers Squibb Company | Tripeptides incorporating deuterium as inhibitors of hepatitis c virus |
-
2012
- 2012-06-11 US US13/492,982 patent/US8691757B2/en active Active
- 2012-06-12 MX MX2013014002A patent/MX2013014002A/es unknown
- 2012-06-12 BR BR112013032049A patent/BR112013032049A2/pt not_active IP Right Cessation
- 2012-06-12 EA EA201391717A patent/EA024173B1/ru not_active IP Right Cessation
- 2012-06-12 CA CA2839400A patent/CA2839400A1/en not_active Abandoned
- 2012-06-12 EP EP12729291.0A patent/EP2721053B1/en not_active Not-in-force
- 2012-06-12 JP JP2014515914A patent/JP6078536B2/ja not_active Expired - Fee Related
- 2012-06-12 WO PCT/US2012/042038 patent/WO2012173983A1/en not_active Ceased
- 2012-06-12 ES ES12729291.0T patent/ES2604690T3/es active Active
- 2012-06-14 TW TW101121400A patent/TW201305173A/zh unknown
- 2012-06-14 AR ARP120102114A patent/AR086934A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112013032049A2 (pt) | 2016-09-13 |
| US20130142754A1 (en) | 2013-06-06 |
| TW201305173A (zh) | 2013-02-01 |
| CA2839400A1 (en) | 2012-12-20 |
| EA024173B1 (ru) | 2016-08-31 |
| MX2013014002A (es) | 2014-03-12 |
| US8691757B2 (en) | 2014-04-08 |
| AR086934A1 (es) | 2014-01-29 |
| JP2014522809A (ja) | 2014-09-08 |
| EA201391717A1 (ru) | 2014-04-30 |
| EP2721053B1 (en) | 2016-10-19 |
| EP2721053A1 (en) | 2014-04-23 |
| CN103732613A (zh) | 2014-04-16 |
| WO2012173983A1 (en) | 2012-12-20 |
| ES2604690T3 (es) | 2017-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102317306B (zh) | 丙型肝炎病毒抑制剂 | |
| JP5487209B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5450604B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5474940B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5221552B2 (ja) | Ｃ型肝炎ウイルス阻害剤としての大環状ペプチド | |
| JP2014522809A (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP5241728B2 (ja) | Ｃ型肝炎ウイルス阻害剤としての大環状ペプチド | |
| CN102307890B (zh) | 丙型肝炎病毒抑制剂 | |
| TWI542589B (zh) | Ｃ型肝炎病毒抑制劑 | |
| JP5529120B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP2012504126A (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP6110846B2 (ja) | Ｃ型肝炎ウイルス阻害剤としての重水素が導入されたトリペプチド | |
| JP2012504129A (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP2011521911A (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| TW200946523A (en) | Hepatitis C virus inhibitors | |
| TW201422620A (zh) | Ｃ型肝炎病毒抑制劑 | |
| JP6342922B2 (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| EP2914598A1 (en) | Hepatitis c virus inhibitors | |
| CN103732613B (zh) | 丙型肝炎病毒抑制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150518 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150518 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20160219 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160607 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160826 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170110 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170116 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6078536 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |